Randomized Phase IIB Evaluation of Weekly Paclitaxel versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysin®) in Recurrent Ovarian, Tubal, or Peritoneal Cancer: an NRG Oncology/Gynecologic Oncology Group Study

OBJECTIVE: To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. PATIENTS AND METHODS: Patients with recurrent or persistent e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Cohn, David E., Sill, Michael W., Walker, Joan L., O'Malley, David, Nagel, Christa I., Rutledge, Teresa L., Bradley, William, Richardson, Debra L., Moxley, Katherine M., Aghajanian, Carol
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570536/
https://ncbi.nlm.nih.gov/pubmed/28756871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.07.135
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados